Staar Surgical Co. Aktie
39,03 €
Deine Einschätzung
Staar Surgical Co. Aktie
Was spricht für und gegen Staar Surgical Co. in den nächsten Jahren?
Pro
Kontra
Rendite von Staar Surgical Co. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | -0,61 % | -0,43 % | -11,01 % | -30,45 % | 34,45 % | -65,01 % | - |
Orasure Tech | -2,16 % | -5,44 % | -7,38 % | -0,44 % | -39,33 % | -40,74 % | -37,61 % |
scPharmaceuticals | 6,49 % | -26,46 % | -19,21 % | -65,65 % | -42,96 % | -28,38 % | - |
SI-BONE Inc | -4,69 % | -11,59 % | -6,87 % | -46,02 % | -35,79 % | -52,34 % | - |
Kommentare
News
STAAR Surgical Reports First Quarter 2024 Results
STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today